GnRH-Antagonisten in der kontrollierten ovariellen Stimulation

[1]  G. Haidl,et al.  Andrology and clinical sciences. , 1998, Human reproduction.

[2]  K. Diedrich,et al.  Komplikationen der assistierten Reproduktion , 1996, Der Gynäkologe.

[3]  K. Diedrich,et al.  Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages , 1996, Journal of Assisted Reproduction and Genetics.

[4]  A. Balen.  The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. , 1995, Human reproduction.

[5]  A. Schally,et al.  Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. , 1995, Human reproduction.

[6]  D. Klingmüller,et al.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. , 1994, Human reproduction.

[7]  B. Tarlatzis,et al.  The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. , 1992, Human reproduction.

[8]  K. Thomas,et al.  Short‐term Utilization of a Gonadotropin‐Releasing Hormone Agonist (Buserelin) for Induction of Ovulation in an in Vitro Fertilization Program , 1988, Annals of the New York Academy of Sciences.

[9]  J. Yovich,et al.  Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase , 1985, British journal of obstetrics and gynaecology.

[10]  K. Diedrich,et al.  Three years of routine vitrification of human zygotes: is it still fair to advocate slow-rate freezing? , 2007, Reproductive biomedicine online.